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Interdigitating dendritic cell sarcoma (IDCS) is a rare tumor derived from interdigitating dendritic cells. Three cases of IDCS associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been described, but no clonal relationship between the 2 neoplasms was demonstrated. We present a detailed case analysis of a CLL/SLL with metachronous IDCS and demonstrate that these 2 neoplasms are clonally related. The IDCS and CLL cells had trisomy 12 and identical monoclonal immunoglobulin heavy chain gene rearrangements. Analysis of transcription factors with a role in myeloid differentiation demonstrated PU.1 up-regulation and C/ EBPα down-regulation in IDCS compared with CLL. High-density array comparative genomic hybridization also identified gains in part of chromosome 16q in IDCS. Our study demonstrates for the first time clonal transformation of CLL/SLL into IDCS. This phenomenon may be triggered by alterations in lineagedetermining transcription programs, which result in transdifferentiation, coupled with additional oncogenic stimuli caused by chromosomal imbalances.
Interdigitating dendritic cells are bone marrow-derived, accessory antigen-presenting cells located in the paracortex of lymph nodes where they interact with T cells and can proliferate in reactive conditions such as dermatopathic lymphadenopathy. Interdigitating dendritic cells are derived from myeloid precursors, which also have the potential to differentiate into monocytes-macrophages. 1 Interdigitating dendritic cell sarcoma (IDCS) is a rare tumor derived from interdigitating dendritic cells. Other neoplasms derived from other related accessory cells and phagocytes include Langerhans cell histiocytosis, Langerhans cell sarcoma, follicular dendritic cell sarcoma, and histiocytic sarcoma.
All of these neoplasms show a propensity for nonrandom association of dendritic cell and histiocytic neoplasms with secondary neoplasms, in particular, malignancies of lymphoid origin. Langerhans cell histiocytosis has been associated with lymphoproliferative disorders, including mycosis fungoides, T-lymphoblastic lymphoma/leukemia, Hodgkin lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). [2] [3] [4] [5] Cases of histiocytic sarcoma, defined as a malignant proliferation of cells with morphologic and immunophenotypic features of mature histiocytes without evidence of acute monocytic leukemia, have been associated with acute lymphoblastic leukemia and low grade B-cell lymphomas (CLL/SLL and follicular lymphoma). [6] [7] [8] [9] About 17% of IDCS cases have been associated with non-Hodgkin lymphomas, including CLL/SLL, mycosis fungoides, precursor T-lymphoblastic leukemia, and follicular lymphoma. [10] [11] [12] [13] [14] A clonal relationship between histiocytic/dendritic cell neoplasms and lymphoid malignancies was first suggested by Wetzler et al 8 when they demonstrated by conventional karyotyping the presence of trisomy 12 in CLL and a subsequent lymph node biopsy specimen involved by histiocytic sarcoma (then called lymphoma of the true histiocytic type) and also residual CLL. The lymph node also harbored additional cytogenetic abnormalities. Common clonal origins were subsequently demonstrated by molecular genetic techniques between precursor T-lymphoblastic lymphoma/leukemia and histiocytic sarcoma, 7 precursor T-lymphoblastic lymphoma/leukemia and Langerhans cell histiocytosis, 4, 5 and most recently, follicular lymphoma and histiocytic/dendritic neoplasms. 9, 15 To date, 3 cases of metachronous and synchronous CLL/SLL and IDCS have been described in the literature, but no clonal relationship between these 2 neoplasms was documented. 10, 11, 14 Herein we report another case of metachronous CLL/SLL and IDCS and demonstrate for the first time a common clonal origin between these 2 tumors. In the recent series of 8 histiocytic/dendritic neoplasms and follicular lymphomas analyzed by Feldman et al, 15 1 case of IDCS was included and demonstrated to be clonally related to a follicular lymphoma, which was identified in the same lymph node. Our study provides additional evidence for an ontogenetic relationship between an IDCS and B-cell lymphoma and documents with convincing molecular evidence that transdifferentiation can also occur in a CLL/SLL clone. In addition, we demonstrated through gene expression and genomic analyses potential mechanisms for transdifferentiative transformation of CLL/SLL to IDCS.
Case Report
The patient is a 77-year-old man with a 3-year history of CLL/SLL. He was followed up expectantly for 2 years, during which time significant lymphadenopathy developed and was treated in an anti-idiotype vaccine study during 6 months, which was discontinued owing to disease progression. At this time, he received 6 cycles of fludarabine plus rituximab therapy and demonstrated a complete response on physical examination and blood counts. Within 4 months, abdominal and shoulder pain developed. The physical examination findings were notable for a 6-cm left axillary lymph node, slight splenic enlargement, and hepatomegaly to 4 cm below the right costal margin. A CBC showed a hemoglobin level of 12.7 g/dL (127 g/L), a platelet count of 13 × 10 3 /μL (13 × 10 9 /L), and a WBC count of 5,600/μL (5.6 × 10 9 /L). A WBC differential count revealed 67% neutrophils (0.67), 25.6% lymphocytes (0.26; absolute lymphocytes of 1,400/μL [1.4 × 10 9 /L]), 6.3% monocytes (0.06), 0.1% eosinophils (0.001), and 1% basophils (0.01). A bone marrow biopsy showed diffuse effacement by CLL. Because of the concern for transformation to high-grade lymphoma (Richter transformation), a left axillary lymph node excisional biopsy was performed. Based on the morphologic and immunophenotypic features, the patient was diagnosed with an IDCS with concurrent CLL/SLL in the lymph node.
Materials and Methods

Histologic and Immunohistochemical Analyses
The case with CLL and IDCS was identified from Weill Cornell Medical College of Cornell University, New York, NY. The CLL and IDCS were diagnosed according to the diagnostic criteria of the World Health Organization by morphologic evaluation and immunophenotypic analysis performed on formalin-fixed, paraffin-embedded tissues. For immunohistochemical analysis, paraffin-embedded tissue sections were stained using a Leica autostainer (Leica Microsystems, Bannockburn, IL) according to the company's protocols, with minor modifications. The antibodies used are listed in ❚Table 1❚. This study was approved by the Weill Cornell Medical College Institutional Review Board.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) assay using the SpectrumOrange-labeled centromeric probe for chromosome 12 (CEP 12) (Vysis/Abbott Molecular, Des Plaines, IL) was performed on a touch prep of the lymph node sample according to the manufacturer's instructions with minor modifications.
Immunoglobulin Gene Rearrangement Analysis by Polymerase Chain Reaction and Sequencing
Genomic DNA isolated from cryopreserved bone marrow aspirate cells or extracted from IDCS tumor cells dissected from the formalin-fixed, paraffin-embedded lymph node sample was subjected to polymerase chain reaction (PCR) analysis for IgH gene rearrangement performed using the IgH Somatic Hypermutation Assay kit (InvivoScribe Technologies, San Diego, CA) with primers targeting the conserved Leader region and the downstream consensus J H gene segments. The amplicon spans framework region (FR) 1, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and CDR3. PCR products were analyzed using agarose gel electrophoresis. To further compare the 2 PCR products derived from the CLL/SLL cells and IDCS cells, the PCR amplicons were purified and sequenced. The sequencing reactions were done on an ABI Automated 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). For somatic hypermutation analysis, sequences of the PCR products were analyzed on IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/).
Array Comparative Genomic Hybridization
Genomic DNA was extracted from frozen bone marrow CLL cells and cryopreserved lymph node tissues that contained more than 80% of IDCS cells. Three micrograms of genomic DNA from each sample was labeled by random priming protocol provided by the manufacturer (Roche NimbleGen, Madison, WI). The 2 cancer samples were labeled with Cy3 (Trilink, San Diego, CA), and each of them was hybridized together with the normal tonsil control sample labeled with Cy5 (Trilink) on the NimbleGen HG18 WG Tiling CGH v2.0D array containing 2.1 million probes (Roche NimbleGen). The arrays were washed and scanned on an Axon 4000B scanner (Molecular Devices, Sunnyvale, CA). The TIFF images were analyzed by NimbleScan 2.4 software (Roche NimbleGen) to obtain fluorescent intensity, and the copy number was further determined using segMNT algorithm with a 10× averaging window and minimum difference in log ratio of 0.1. The copy number variation result was visualized using SignalMap 1.9 software from Roche NimbleGen.
Reverse-Transcriptase Real-Time PCR
Total RNA was extracted from frozen bone marrow CLL cells and cryopreserved lymph node tissues that contained at least 80% of IDCS cells and treated with RNase-free DNase I. Complementary DNA (cDNA) was synthesized using random primers. Monoplex real-time PCR was conducted by using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The PCR reaction was done using 50-ng cDNA templates under the following PCR conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 58°C for 30 seconds, and 72°C for 1 minute. A standard curve, consisting of serially diluted K562 cell line RNA, was included on each 96-well reaction plate for each run. Each cDNA template was assayed in duplicate, and each sample was run 2 independent times. Messenger RNA (mRNA) quantities were performed using the standard curve method, normalized to the endogenous control gene β-glucuronidase, and expressed as relative values. Primers and probes for real-time detection of PU.1, C/EBPα, C/ EBPβ, and β-glucuronidase mRNA were purchased from Applied Biosystems as predeveloped assay reagents.
Results
Histologic and Immunophenotypic Findings
The bone marrow biopsy showed hypercellular marrow replaced by a diffuse proliferation of monotonous small round lymphocytes with clumped chromatin and scant cytoplasm ❚Image 1A❚. Based on flow cytometric and immunohistochemical analyses (data not shown), these lymphocytes were κ-restricted CD20+ B cells that coexpressed CD5 and CD23 and were positive for ZAP70. These findings were diagnostic of CLL/SLL.
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❚Image 1❚ Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in bone marrow and "composite" interdigitating dendritic cell sarcoma (IDCS) and CLL/SLL in lymph node. A, A bone marrow biopsy showed a hypercellular marrow replaced by a diffuse proliferation of small lymphocytes in CLL/SLL (H&E, ×4). B, A lymph node biopsy showed that the majority of the lymph node is occupied by diffuse sheets and interconnecting cords of IDCS cells admixed with residual islands of CLL/SLL (H&E, ×10). C, High-power microscopic features of IDCS in the lymph node. The tumor cells are large with oval to round nuclei, vesicular chromatin, and occasionally prominent nucleoli. Some nuclei are indented or rarely show increased lobations. The cytoplasm is abundant with indistinct cell borders (H&E, ×400). D, The CLL/SLL in the lymph node is composed predominantly of small, round lymphocytes with scant cytoplasm. Few scattered larger lymphocytes are seen (H&E, ×400).
The lymph node biopsy demonstrated extensive architectural effacement due to a paracortical proliferation of large malignant cells with round to ovoid nuclei, vesicular chromatin, and variably prominent nucleoli. In addition, the cells exhibited abundant eosinophilic cytoplasm and indistinct cell borders. Mitotic activity was high with about 10 mitotic figures per 10 high-power fields. The tumor cells were intermixed with scattered small lymphocytes with clumped chromatin and scant cytoplasm ❚Image 1B❚, ❚Image 1C❚, and ❚Image 1D❚.
Results of the immunohistochemical stains are summarized in Table 1 . The large tumor cells did not significantly exhibit a B-cell phenotype. They were negative for CD20 and CD79a and only weakly expressed PAX5. These tumor cells were immunoreactive for S-100, HLA-DR, and fascin and lacked expression of CD1a, CD163, CD21, CD23, CD35, myeloperoxidase, CD34, and CD117 ❚Image 2❚. They showed a moderate proliferation rate (40%). A minority of the cells overexpressed p53. The background lymphocytes were positive for CD5, CD23, CD43, and CD20. These histopathologic and immunophenotypic findings were consistent with an IDCS with concurrent CLL in the lymph node.
Clonality Analysis by PCR and FISH
An area of IDCS cells dissected from the lymph node and bone marrow CLL cells were subjected to PCR reactions to assess the status of IgH gene rearrangements. Both tumors showed identical IgH rearrangements ❚Image 3A❚. Sequence analysis revealed identical V-J junction sequences with 100% homology to the V H 4-39 germline sequence ❚Image 3B❚.
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❚Image 2❚ Immunoreactivities of the IDCS cells. These malignant cells are positive for S-100 (A) and fascin (B) but negative for CD1a (C) and CD163 (D; which highlights normal macrophages). Surprisingly, C/EBPα transcripts decreased by more than 5-fold in IDCS, and there was no significant change in the levels of C/EBPβ. These results support a role of these transcription factors, particularly PU.1 and C/EBPα, in transdifferentiation of CLL to IDCS. To further delineate the mechanisms of transformation of CLL/SLL to IDCS, high-density array comparative genomic hybridization was used to identify additional gene copy gains or losses in the IDCS compared with the CLL/ SLL. As expected, trisomy 12 was detected in the CLL/SLL In addition, FISH analysis identified trisomy 12 in the small CLL/SLL cells and the larger IDCS cells in the lymph node touch prep ❚Image 4❚. These findings demonstrate convincingly that the IDCS and CLL are clonally related.
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Gene Expression and Genome Alterations Associated With Transformation From CLL/SLL to IDCS
The transcription factors PU.1 and C/EBP have been implicated in transdifferentiation of B cells into macrophages in a murine model 16, 17 and transdifferentiation of follicular lymphoma into histiocytic/dendritic cell sarcomas in a clinical setting. 15 To determine if alterations in expression of these transcriptional factors may contribute to transdifferentiation in our case, we compared mRNA expression levels of PU.1, C/EBPα, and C/EBPβ between the bone marrow CLL E F
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The tumor cells show immunoreactivity for lysozyme (E) and CD68 (F) with a Golgi pattern. The tumor cells are weakly positive to negative for PAX5 (G) and lack CD20 (H) (A-H, ×200).
and IDCS. In addition, 2 levels of chromosomal gains were observed in part of the long arm of chromosome 16 in the IDCS compared with the CLL/SLL ❚Image 6❚. Regions 1 to 2, 4 to 6, and 7 to 8 had moderate gains, whereas regions 2 to 4 (ch 16: ~62,000,000-68,000,000) and 6 to 7 (ch 16: ~76,000,000-81,000,000) had high gains. Genes that reside in the amplified regions are listed in ❚Table 2❚. Deregulation of some of these genes by gene amplification may have a role in the transformation process. Among the genes within the amplified region are 2 family members of nuclear factor of activated T cells (NFAT), NFATc3 and NFAT5, and phospholipase C, gamma 2 (PLCG2). All 3 genes are located in the highly amplified regions. Their relevance in the transformation of CLL to IDCS is discussed subsequently.
Discussion
To date, there have been 3 documented cases of CLL/ SLL in association with IDCS. In 2 of them, IDCS developed following a history of CLL/SLL, and in the other case, the 2 neoplasms were synchronous. 10, 11, 14 A clonal relationship between CLL/SLL and histiocytic or dendritic cell neoplasms has been alluded to previously but was not convincingly demonstrated. 8, 10 Our study demonstrated for the first time a ❚Image 4❚ Trisomy 12 in chronic lymphocytic leukemia (CLL) and interdigitating dendritic cell sarcoma (IDCS). In situ hybridization (A) using a chromosome 12 probe on a touch preparation of the lymph node (B, rapid Romanowsky, ×1,000) identified trisomy 12 in the small CLL/small lymphocytic lymphoma lymphocytes (arrows) and the larger IDCS cells (arrowheads).
scenario, which is supported by the following clinical and genetic observations. First, the occurrence of IDCS has been preceded by a history of CLL and was associated with deteriorating clinical presentation. Second, IDCS cells harbored additional genome changes in chromosome 16 (see later text) in addition to trisomy 12 present in the IDCS and in the CLL cells, consistent with disease progression. Third, IgHV4-39*01 was the DNA sequence used in the clonal IgH gene rearrangements of the CLL and IDCS. Multivariate analysis showed that IgHV4-39 use in CLL is an independent risk factor for transformation to large cell common clonal origin for CLL/SLL and IDCS, evidenced by the presence of identical V-J junction sequences and trisomy 12 in both tumors. In fact, it probably represents the first definitive demonstration of a clonal relationship between CLL/SLL and a histiocytic/dendritic cell neoplasm. The common clonal origin between the CLL and IDCS in this patient suggests that IDCS may represent a transdifferentiative transformation of the CLL/SLL to IDCS. There is also the possibility that the CLL and IDCS may arise from a common precursor that differentiates along different ontogenic pathways. We strongly favor the transformation 76613943  76623499  CLEC3A  76691051  76870094  WWOX  78185731  78192112  MAF  79132354  79142040  DYNLRB2  79195178  79395676  CDYL2  79567201  79597997  C16orf61  79597603  79624210  CENPN  79626958  79638452  ASCIZ  79644602  79668373  C16orf46  79673431  79687481  GCSH  79691984  79811476  PKD1L2  79829796  79882248  BCMO1  79906075  79971441  GAN  80036394  80302866  CMIP  80370430  80549399  PLCG2  80588752  80602594  HSPC105  80626363  80689638  HSD17B2  80739268  80761330  MPHOSPH6  81218078  82387698  CDH13  82399093  82404095  HSBP1  82490230  82507286  MLYCD  82540172  82557439  OSGIN1  82559737  82593878  EFCBP2  82600889  82633263  LOC146167  82644871  82708018  MBTPS1  82713388  82736265  HSDL1  82736365  82769025  LRRC50  82768962  82778163  TAF1C  82782244  82788273  ADAD2  82813325  82830857  KCNG4  82885901  82920947  WFDC1  82959633  83055293  ATP2C2  83068611  83095794  KIAA1609  83156706  83209170  COTL1  83239631  83253416  C16orf44  83291055  83371026  USP10  83411112  83500615  CRISPLD2  83565572  83602642  ZDHHC7  83618910  83685327  KIAA0513  83689465  83703615  FAM92B  84204424  84267311  KIAA0182  84268781  84280081  GINS2   66567067  66571867  DPEP3  66578800  66590857  DPEP2  66612674  66615460  DDX28  66614704  66670684  DUS2L  66676875  66818338  NFATC3  66819950  66827637  RBM35B  66836747  66852460  LYPLA3  66855923  66893223  SLC7A6  66892020  66902349  SLC7A6OS  66902445  66948663  PRMT7  66949732  67039905  SMPD3  67131161  67158539  ZFP90  67236276  67290442  CDH3  67328695  67426945  CDH1  67435009  67676586  TMCO7  67697660  67710118  HAS3  67709413  67723985  CTF8  67724047  67760424  CIRH1A  67778550  67900455  SNTB2  67902787  67916446  VPS4A  67920024  67921999  PDF  67920024  67931014  COG8  67931046  67934508  NIP7  67934660  67943190  TMED6  67947035  67977374  TERF2  68015998  68057668  CYB5B  68156497  68296054  NFAT5  68300805  68318034  NQO1  68333275  68346330  NOB1  68353774  68533144  WWP2  68542310  68555388  LOC348174  68705029  68752685  PDPR  68765428  68778297  MGC34761  68841634  68843334  EXOSC6  68843797  68880913  AARS  68890572  68925230  DDX19B  68938324  68964780  DDX19A  68970838  69030492  ST3GAL2  69045998  69071677  FUK  69071973  69114958  COG4  69115201  69163701  SF3B3  69237968  69252085  C16orf77  69252608  69277455  ABBA-1  69278844  69392562  VAC14  69398789  69822070  HYDIN  69873703  69880816  FLJ11171  69950126  69981843  CALB2  70039013  70053618  ZNF23  70065476  70080755  ZNF19  70117561  70129914  CHST4  70158254  70168496  TAT  70217570  70233367  MARVELD3  70236354  70306205  PHLPPL  70320407  70400477  AP1G1  70451089  70474913  LOC55565  70486946  70520407  KIAA0174  70600143  70616455  DHODH  70646008  70652458  HP  70654625  70668645  HPR  70676258  70685015  TXNL4B  70685115  70704311  DHX38  70710499  70763525  PMFBP1  71374288  71639775  ZFHX3  71684024  71685173  LOC283902  72888181  72897685  PSMD7  72969372  72983513  LOC440348  73000031  73012791  LOC497190   57055117  57105023  NDRG4  57106927  57111051  SETD6  57111356  57221251  CNOT1  57257798  57276175  FLJ10815  57298535  57325747  GOT2  60244735  60627537  CDH8  63875902  64167704  LOC283867  64958063  64996189  CDH5  65100852  65141816  TK2  65143966  65157655  CKLF  65157794  65170539  CMTM1  65170851  65179676  CMTM2  65195702  65205294  CMTM3  65206154  65288111  CMTM4  65312299  65343026  DYNC1LI2  65394282  65422380  APPBP1  65435782  65445548  CA7  65471936  65479356  PDP2  65499526  65510267  CDH16  65513089  65516920  RRAD  65523466  65525804  FAM96B  65525847  65536493  CES2  65552638  65566553  CES3  65580133  65601158  FLJ37464  65620550  65692457  CBFB  65701415  65739941  C16orf70  65739506  65742403  MGC4655  65745589  65751313  TRADD  65751391  65755578  FBXL8  65754857  65761349  HSF4  65765370  65767125  NOL3  65767006  65775384  LOC653319  65775783  65781608  EXOC3L  65783568  65790321  E2F4  65790528  65795427  ELMO3  65798543  65818402  LRRC29  65818516  65820683  HSPC171  65820794  65838926  FHOD1  65840355  65863594  SLC9A5  65868913  65880883  PLEKHG4  65880893  65918162  KCTD19  65918247  65976602  LRRC36  65981214  65984922  TPPP3  65985828  66007878  ZDHHC1  66022536  66028953  HSD11B2  66029417  66072590  ATP6V0D1  66073974  66075217  AGRP  66120254  66138189  FAM65A  66153964  66230588  CTCF  66236530  66248971  RLTPR  66248915  66252219  ACD  66252351  66254181  PARD6A  66254350  66258129  C16orf48  66258217  66260162  LOC388284  66265944  66310720  GFOD2  66314506  66398056  RANBP10  66398510  66419471  TSNAXIP1  66419560  66438862  CENPT  66433713  66435598  THAP11  66438319  66462719  NUTF2  66464499  66475906  EDC4  66476281  66477771  NRN1L  66484715  66521081  PSKH1  66520974  66523266  CTRL  66525907  66528254  PSMB10  66531287  66535516  LCAT  66535730 66560026 SLC12A4 84298624  84342190  C16orf74  84369736  84390601  COX4NB  84390696  84398106  COX4I1  84490274  84513710  IRF8  85101633  85105570  FOXF1  85121283  85146342  MTHFSD  85158442  85159947  FOXC2  85169615  85172804  FOXL1  85920444  85974864  FBXO31  85983319  85995880  MAP1LC3B  85997352  86082961  ZCCHC14  86193999  86289260  JPH3  86298922  86357043  KLHDC4  86421130  86460601  SLC7A5  86479125  86527613  CA5A  86542538  86668424  BANP  87047514  87129074  ZFPM1  87147612  87164049  FLJ45530  87164344  87225756  NHN1  87232501  87234382  IL17C  87237198  87244958  CYBA  87245848  87256996  MVD  87271590  87280383  SNAI3  87290409  87300301  RNF166  87300391  87309285  LOC348180  87309255  87330160  FAM38A  87397686  87403166  CDT1  87403379  87405843  APRT  87407643  87450885  GALNS  87451008  87455021  TRAPPC2L  87455534  87460515  LOC390748  87468767  87570902  CBFA2T3  87687824  87749670  LOC197322  87765663  87789400  CDH15  87811611  87822864  ZNF778  87861535  88084470  ANKRD11  88102305  88151674  SPG7  88154590  88157349  RPL13  88169676  88191154  CPNE7  88214500  88232338  DPEP1  88238344  88251630  CHMP1A  88251710  88265176  C16orf55  88280576  88290263  CDK10  88290265  88295600  SPATA2L  88301041  88314895  C16orf7  88314933  88333811  ZNF276  88331459  88410566  FANCA  88422407  88465228  SPIRE2  88467526  88505287  TCF25  88512526  88514885  MC1R  88517245  88530006  TUBB3  88542683  88561968  DEF8  88563702  88566443  MGC16385  88598781  88613438  DBNDD1  88616508  88638880  GAS8  88622816  88623810  C16orf3  88650474  88669839  PRDM7 lymphoma. 18 Thus, our results support the concept that transdifferentiation can occur during clonal evolution of mature low-grade B-cell lymphomas, a concept that was first demonstrated by Feldman et al 15 in their analysis of a case series of 8 follicular lymphomas with associated histiocytic/dendritic cell sarcomas. In that series, only a single case of IDCS was included. Thus, not only can indolent B-cell lymphomas like CLL and follicular lymphoma appear capable of transforming to aggressive B-cell lymphomas as part of their disease evolution, but also they can undergo clonal transformation into histiocytic/dendritic neoplasms via transdifferentiation. The molecular mechanisms of transdifferentiation by mature B-cell lymphomas into histiocytic/dendritic neoplasms are not clear. It has been thought that activation of the transcriptional program related to the myeloid-macrophage lineage and silencing of B-cell transcription factors may have a role. 16 Two master regulators of myelopoiesis are the Etsfamily transcription factor PU.1 and the CCAAT/enhancer binding protein (C/EBP), in particular C/EBPα and C/EBPβ. PU.1 is required for the development of the macrophage and the lymphoid lineages. 19 It appears to function as a primary lineage determinant in B-cell/macrophage lineage decisions. PU.1, which is present in lower levels in B cells than macrophages, promotes B-cell differentiation in fetal liver precursors at low levels and macrophage differentiation at high levels. 20 C/EBPα is essential for the development of granulocytes. 21 Gene knockout of C/EBPβ resulted in functional defects in macrophages. 22 These transcription factors have also been shown to induce transdifferentiation of committed B cells into non-B cells. Overexpressed C/EBPα or C/ EBPβ can synergize with high levels of PU.1 to reprogram committed B cells into macrophages. 17 Consistent with these experimental data, all cases of histiocytic/dendritic sarcomas transdifferentiated from follicular lymphoma showed high PU.1 and C/EBPβ expression (C/EBPα not tested) based on immunohistochemical analysis, although it was not explicitly demonstrated how these levels of expression were compared with the lymphoma cells. 15 To further investigate the role of these transcription factors in transdifferentiation of B-cell lymphomas to histiocytic/ dendritic neoplasms, we compared in our study the expression levels of PU.1, C/EBPα, and C/EBPβ between CLL and IDCS. This comparison revealed up-regulation of PU.1, whereas C/EBPα was down-regulated in IDCS with no significant difference in expression levels of C/EBPβ between the 2 tumors. These results are in line with the known characterized functions of these transcription factors in dendritic cell development. A high level of PU.l facilitates dendritic cell development from myeloid progenitors and CD34+ cord blood cells, and this function can be antagonized by C/EBPα. 23, 24 Thus, it is conceivable that up-regulation of PU.1 and down-regulation of C/EBPα may promote transdifferentiation of CLL/SLL to IDCS. This finding also provides in vivo evidence that the plasticity of B cells to reprogram to specific non-B-cell lineages depends on the levels of PU.1 and C/EBPα/β.
Start Stop Gene
Besides activation of the gene expression program related to the myeloid-macrophage-dendritic lineages, attenuation of the activity of the B-cell commitment transcription factors such as PAX5 is also believed to have an important role in the transdifferentiation of mature B-cell lymphomas to histiocytic/dendritic neoplasms. Absence of PAX5 has been demonstrated in histiocytic sarcoma and IDCS transdifferentiated from follicular lymphomas. 15 In our current case, PAX5 was very weakly expressed in IDCS. It was previously demonstrated that C/EBPα, directly or indirectly, inhibits PAX5 expression. 17 However, C/EBPα was down-regulated in IDCS in this case, suggesting that PAX5 may be inhibited by an alternative mechanism.
Array comparative genomic hybridization was performed to identify additional genetic lesions that may promote transformation of CLL/SLL to IDCS. Amplification of part of 16q was identified as the only additional alteration in the IDCS compared with the CLL/SLL. It is interesting that this region contains 2 members of the NFAT family, NFAT5 and NFATC3, as well as PLCG2. The latter is capable of activating NFAT and NF-κB. NFAT and NF-κB are related proteins that belong to the REL superfamily of transcription factors, which have crucial roles in the activation, proliferation, and apoptosis of cells in the immune system. 25, 26 Constitutive activation of NF-κB and NFAT transcription factors has been shown to be important for proliferation and survival of aggressive lymphoma cells through regulation of the B lymphocyte stimulator (BLyS) pathway. 27 It is interesting that BLyS can also promote dendritic cell activation and maturation. 28 It is conceivable that while alterations of transcription factor programs related to macrophage and/or dendritic cell differentiation, as well as B-cell differentiation, are critical for lineage switch and transdifferentiation, increased activity of transcription factors such as NFAT and NF-κB with pluripotent functions in the immune system may provide the additional oncogenic stimuli necessary for a complete transformation of CLL to IDCS.
Molecular analysis of this rare case of clonal transformation of CLL to IDCS illustrates and expands the spectrum of cases of B-cell lymphomas in which transdifferentiation to histiocytic/dendritic cell neoplasms occurs and offers potential explanations for this unusual transformation process. Recently, about 40% of sporadic histiocytic/dendritic cell sarcomas were found to harbor monoclonal immunoglobulin gene rearrangements. 29 This finding raises the intriguing possibility that at least a proportion of these tumors may actually be derived from B cells and is also compatible with the transdifferentiation hypothesis, as suggested by this case and by Feldman et al. 15 Analysis of additional cases of
